July 5, 2022

News Collective

Complete New Zealand News World

Pfizer acquires ReViral for $525 million and expands its RSV portfolio

Pfizer acquires ReViral for $525 million and expands its RSV portfolio

A new agreement in the health sector. The US drugmaker and ReViral have reached an acquisition agreement under which Pfizer It will acquire the British company for $525 millionAccording to the two companies, in a statement.

ReViral is focused on developing and commercializing new treatments that target respiratory syncytial virus (RSV), a respiratory pathogen that can cause Serious and life-threatening infections of the lower respiratory tract.

“The product line continues to expand, through our research and development efforts such as experimental vaccine programs, as well as strategic investments,” stressed Albert Burla, president of Pfizer. Respiratory syncytial virus is estimated to cause infections in approximately 64 million people. Resulting in about 160,000 deaths worldwide each year.

ReViral has a range of therapeutic candidates, including sisunatovir, an orally administered inhibitor designed to prevent RSV fusion with host cells.

“Currently, treatment options for RSV are very limited and focus primarily on supportive care,” said Annaliesa Anderson, Pfizer’s vice president and chief scientific officer.

Alex Sapir, CEO of ReViral, concluded, “This acquisition is confirmation of the company’s team’s antiviral experience. Pfizer is positioned as an ideal partner given its commitment to RSV through its ongoing vaccine program.” Clifford Chance LLP has acted as legal counsel for Pfizer. Centerview Partners LLC, Goodwin Procter LLP, and BofA Securities did the same in the ReViral case.

See also  Nuki introduces its new generation of smart locks